Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: Expansion of a murine model of microbicide safety

Antiviral Therapy

Volumn 14, Issue 8, 2009, Pages 1113-1124

  Wilson, Sarah S ^a   Cheshenko, Natalia ^a   Fakioglu, Esra ^a   Mesquita, Pedro M M ^a   Keller, Marla J ^a   Herold, Betsy C ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAP JUNCTION PROTEIN; HYDROXYETHYLCELLULOSE; NONOXINOL 9; PLACEBO; PRO 2000; TENOFOVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; EPITHELIUM CELL; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INFECTION SENSITIVITY; INFLAMMATION; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; VIRUS PARTICLE;

ADENINE; ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTI-INFECTIVE AGENTS; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; MICE; MICE, INBRED BALB C; NAPHTHALENESULFONATES; NONOXYNOL; PHOSPHONIC ACIDS; POLYMERS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT;

EID: 73449131509     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1463     Document Type: Article

References (47)

1. Van Damme L, Chandeying V, Ramjee G, et al. Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers. AIDS 2000; 14:85-88.
2. Honey K. Microbicide trial screeches to a halt. J Clin Invest 2007; 117:1116.
3. Check E. Scientists rethink approach to HIV gels. Nature 2007; 446:12.
4. Cohen J. AIDS research. Promising AIDS vaccine's failure leaves field reeling. Science 2007; 318:28-29.
5. HIV vaccine failure prompts Merck to halt trial. Nature 2007; 449:390.
6. Eckstein P, Jackson MC, Millman N, Sobrero AJ. Comparison of vaginal tolerance tests of spermicidal preparations in rabbits and monkeys. J Reprod Fertil 1969; 20:85-93.
7. Schwartz JL, Mauck C, Lai JJ, et al. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study. Contraception 2006; 74:133-140.
8. Fichorova RN, Tucker LD, Anderson DJ. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis 2001; 184:418-428.
9. Svensson A, Bellner L, Magnusson M, Eriksson K. Role of IFN-α/β signaling in the prevention of genital herpes virus type 2 infection. J Reprod Immunol 2007; 74:114-123.
10. Serwadda D, Gray RH, Sewankambo NK, et al. Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda. J Infect Dis 2003; 188:1492-1497.
11. Celum C, Levine R, Weaver M, Wald A. Genital herpes and human immunodeficiency virus: double trouble. Bull World Health Organ 2004; 82:447-453.
12. Moss GB, Clemetson D, D'Costa L, et al. Association of cervical ectopy with heterosexual transmission of human immunodeficiency virus: results of a study of couples in Nairobi, Kenya. J Infect Dis 1991; 164:588-591.
13. Myer L, Wright TC, Jr., Denny L, Kuhn L. Nested case-control study of cervical mucosal lesions, ectopy, and incident HIV infection among women in Cape Town, South Africa. Sex Transm Dis 2006; 33:683-687.
14. Linehan MM, Richman S, Krummenacher C, Eisenberg RJ, Cohen GH, Iwasaki A. In vivo role of nectin-1 in entry of herpes simplex virus type 1 (HSV-1) and HSV-2 through the vaginal mucosa. J Virol 2004; 78:2530-2536.
15. Galen B, Cheshenko N, Tuyama A, Ramratnam B, Herold BC. Access to nectin favors herpes simplex virus infection at the apical surface of polarized human epithelial cells. J Virol 2006; 80:12209-12218.
16. Quayle AJ, Porter EM, Nussbaum AA, et al. Gene expression, immunolocalization, and secretion of human defensin-5 in human female reproductive tract. Am J Pathol 1998; 152:1247-1258.
17. Valore EV, Park CH, Quayle AJ, Wiles KR, McCray PB, Jr., Ganz T. Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. J Clin Invest 1998; 101:1633-1642.
18. John M, Keller MJ, Fam EH, et al. Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J Infect Dis 2005; 192:1731-1740.
19. Hazrati E, Galen B, Lu W, et al. Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J Immunol 2006; 177:8658-8666.
20. Cole AM. Innate host defense of human vaginal and cervical mucosae. Curr Top Microbiol Immunol 2006; 306:199-230.
21. Mayer KH, Maslankowski LA, Gai F, et al. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 2006; 20:543-551.
22. Klasse PJ, Shattock R, Moore JP. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med 2008; 59:455-471.
23. Cheshenko N, Keller MJ, MasCasullo V, et al. Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob Agents Chemother 2004; 48:2025-2036.
24. Scordi-Bello IA, Mosoian A, He C, et al. Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob Agents Chemother 2005; 49:3607-3615.
25. Karim SA, Coletti A, Richardson B, et al. Safety and effectiveness of vaginal microbicides BufferGel and 0.5% PRO 2000/5 gel for the prevention of hiv infection in women: results of the HPTN 035 trial. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada.
26. Hendrickson BA, Guo J, Brown I, et al. Decreased vaginal disease in J-chain-deficient mice following herpes simplex type 2 genital infection. Virology 2000; 271:155-162.
27. Geraghty RJ, Krummenacher C, Cohen GH, Eisenberg RJ, Spear PG. Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science 1998; 280:1618-1620.
28. Taylor JM, Lin E, Susmarski N, et al. Alternative entry receptors for herpes simplex virus and their roles in disease. Cell Host Microbe 2007; 2:19-28.
29. Wang W, Owen SM, Rudolph DL, et al. Activity of alpha- and theta-defensins against primary isolates of HIV-1. J Immunol 2004; 173:515-520.
30. Quiñones-Mateu ME, Lederman MM, Feng Z, et al. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS 2003; 17:F39-F48.
31. Guo CJ, Tan N, Song L, Douglas SD, Ho WZ. Alpha-defensins inhibit HIV infection of macrophages through upregulation of CC-chemokines. AIDS 2004; 18:1217-1218.
32. Albanesi C, Fairchild HR, Madonna S, et al. IL-4 and IL-13 negatively regulate TNF-alpha- and IFN-gamma-induced beta-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3. J Immunol 2007; 179:984-992.
33. Mesquita PM, Cheshenko N, Wilson SS, et al. Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J Infect Dis 2009; 200:599-608.
34. Cheshenko N, Herold BC. Glycoprotein B plays a predominant role in mediating herpes simplex virus type 2 attachment and is required for entry and cell-to-cell spread. J Gen Virol 2002; 83:2247-2255.
35. Galen BT, Martin AP, Hazrati E, et al. A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety. J Infect Dis 2007; 195:1332-1339.
36. Mineshiba J, Myokai F, Mineshiba F, Matsuura K, Nishimura F, Takashiba S. Transcriptional regulation of β-defensin-2 by lipopolysaccharide in cultured human cervical carcinoma (HeLa) cells. FEMS Immunol Med Microbiol 2005; 45:37-44.
37. Kaiser V, Diamond G. Expression of mammalian defensin genes. J Leukoc Biol 2000; 68:779-784.
38. Liu L, Wang L, Jia HP, et al. Structure and mapping of the human β-defensin HBD-2 gene and its expression at sites of inflammation. Gene 1998; 222:237-244.
39. Corbeil LB, Chatterjee A, Foresman L, Westfall JA. Ultrastructure of cyclic changes in the murine uterus, cervix, and vagina. Tissue Cell 1985; 17:53-68.
40. Kaushic C, Ashkar AA, Reid LA, Rosenthal KL. Progesterone increases susceptibility and decreases immune responses to genital herpes infection. J Virol 2003; 77:4558-4565.
41. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002; 360:971-977.
42. Phillips DM, Zacharopoulos VR. Nonoxynol-9 enhances rectal infection by herpes simplex virus in mice. Contraception 1998; 57:341-348.
43. Cone RA, Hoen T, Wong X, Abusuwwa R, Anderson DJ, Moench TR. Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission. BMC Infect Dis 2006; 6:90.
44. Catalone BJ, Kish-Catalone TM, Budgeon LR, et al. Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides. Antimicrob Agents Chemother 2004; 48:1837-1847.
45. Li Q, Estes, JD, Schlievert, PM, et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009; 458:1034-1038.
46. + T cells to HIV-1-infected monocyte-derived macrophages, dendritic cells, and lymph nodes. J Immunol 2005; 174:4892-4900.
47. Denton PW, Estes JD, Sun Z, et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 2008; 5:e16.